News
Novavax Inc. closed 60.47% below its 52-week high of $17.81, which the company achieved on July 26th.
7d
Zacks Investment Research on MSNIs Most-Watched Stock Novavax, Inc. (NVAX) Worth Betting on Now?Novavax (NVAX) has recently been on Zacks.com's list of the most searched stocks. Therefore, you might want to consider some ...
Novavax reported revenues of $666.66 million in the last reported quarter, representing a year-over-year change of +610.3%. EPS of $2.93 for the same period compares with -$1.05 a year ago.
1d
Zacks Investment Research on MSNNovavax (NVAX) Dips More Than Broader Market: What You Should KnowNovavax (NVAX) closed the most recent trading day at $6.61, moving -2.79% from the previous trading session. The stock fell short of the S&P 500, which registered a loss of 0.79% for the day. At the ...
Novavax (NVAX) closed at $6.36 in the latest trading session, marking a -2.15% move from the prior day. This move lagged the ...
The stock's fall snapped a three-day winning streak.
18d
Zacks Investment Research on MSNNovavax (NVAX) Ascends While Market Falls: Some Facts to NoteNovavax (NVAX) closed at $6.41 in the latest trading session, marking a +1.75% move from the prior day. The stock's performance was ahead of the S&P 500's daily loss of 0.22%. On the other hand, the ...
Novavax (NasdaqGS:NVAX) recently reported initial results from its Phase 3 trial for its COVID-19-Influenza Combination and seasonal influenza vaccines, which showed immune responses comparable to ...
The leader of the U.S. FDA's division that oversees vaccines, Vinay Prasad, overruled the recommendations of his agency's ...
Novavax Inc. closed 64.23% below its 52-week high of $17.81, which the company achieved on July 26th.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results